Guardant Health Inc

Stock Chart, Company Information, and Scan Results

$99.50(as of Nov 19, 3:59 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Guardant Health Inc Company Information, Fundamentals, and Technical Indicators

Stock Price$99.50
Ticker SymbolGH
ExchangeNasdaq
SectorHealthcare
IndustryDiagnostics & Research
Employees1,999
CountyUSA
Market Cap$12,412.1M
EBIDTA-402.2M
10-Day Moving Average96.65
P/E Ratio-31.28
20-Day Moving Average89.91
Forward P/E Ratio0.00
50-Day Moving Average73.06
Earnings per Share-3.19
200-Day Moving Average53.76
Profit Margin-34.96%
RSI73.14
Shares Outstanding129.9M
ATR5.25
52-Week High105.27
Volume4,720,575
52-Week Low29.91
Most Recent Support Level90.44
Book Value-354.5M
Most Recent Resistance Level99.73
P/B Ratio-35.19
Upper Keltner101.72
P/S Ratio13.82
Lower Keltner78.11
Debt-to-Equity Ratio101.72
Next Earnings Date02/19/2026
Cash Surplus343.1M
Next Ex-Dividend DateUnknown

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company provides precision oncology testing services comprising Guardant360, a panel of genetic tests; Guardant360 LDT that measures 730+ genes and supports all guideline-recommended biomarkers; Guardant360 CDx Test, a liquid biopsy test; Guardant360 Response Test, a blood-only liquid biopsy; Guardant360 TissueNext Test, a tissue-based test with AI-powered PD-L1 detection; GuardantINFINITY Test that provides insights into the complexities of tumor molecular profiles and immune response to advance cancer research and therapy development; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI blood test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It also offers Shield Test; Guardant Reveal Test for adjuvant treatment and surveillance settings in early-stage cancer patients; and Smart Liquid Biopsy Platform. In addition, the company provides development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kit fulfillment and delivery of Shield screening tests. The company was incorporated in 2011 and is headquartered in Palo Alto, California.

Guardant Health Inc In Our Stock Scanner

As of Nov 20, 2025
example chart graphic
Scan Name: Increasing Profit MarginScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: 52-Week HighScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Unusual VolumeScan Type: Stock Indicator Scans
As of ---
example chart graphic
Scan Name: Low PB RatioScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Uptrending StocksScan Type: Chart Pattern Scans
As of ---
example chart graphic
Scan Name: Cash SurplusScan Type: Stock Fundamentals
As of ---

Join Our Free Email List

Get emails from us about ways to potentially make money in the stock market.

This site uses cookies to provide you with an optimal user experience. By using StockMarketGuides.com, you accept our use of cookies.